Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0324
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-07-20T08:46:27.908158Z
status: published
lens: trace
sector: health
headline: Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction
dek: BACKGROUND: A multimodal AI (MMAI) model has been validated in prostate biopsy specimens to guide treatment intensification in men receiving radiation. The MMAI has been explored to an extent for prostatectomy patients and has not yet been examined in relation to established genomic scores. METHODS: We applied the MMAI biopsy model to a tissue microarray (TMA) of 424 prostatectomy cases with long-term follow-up. MMAI scores were derived from digitized pathology images and clinical variables. Associations with bi…
gain_title: In 414 prostatectomy cases, the MMAI score derived from digitized pathology images was associated with long-term biochemical recurrence and metastasis, and when combined with genomic CCP score reached the highest discrimination for metastasis.
problem_title: MMAI lost independent prognostic value after adjustment for CAPRA clinical risk score and did not outperform established clinical tools for postprostatectomy outcome prediction.
trace_subject: prediction of metastasis after prostatectomy using MMAI
gain_reading: In 414 prostatectomy cases, the MMAI score derived from digitized pathology images was associated with long-term biochemical recurrence and metastasis, and when combined with genomic CCP score reached the highest discrimination for metastasis.
gain_evidence: MMAI was significantly associated with BCR (HR 1.04, 95% CI 1.02 to 1.06) and metastasis (HR 1.05, 95% CI 1.02 to 1.07) | The model combining MMAI and CCP achieved the highest discrimination for metastasis (c-index 0.76)
problem_reading: MMAI lost independent prognostic value after adjustment for CAPRA clinical risk score and did not outperform established clinical tools for postprostatectomy outcome prediction.
problem_evidence: MMAI was not independently prognostic after adjustment for CAPRA | Although not outperforming established clinical tools
quick_read: By July 2026, investigators had tested a multimodal AI model originally validated in prostate biopsy specimens on a tissue microarray of 424 prostatectomy cases, generating scores for 414 patients. At 10 years, recurrence-free survival was 74% and metastasis-free survival 96%, and MMAI scores were associated with both endpoints in univariable models.

The finding matters because it suggests pathology AI developed for biopsies can provide prognostic signal from prostatectomy TMA spots and add complementary information to genomic CCP scores, reaching c-index 0.76 for metastasis. Uncertainty remains because MMAI was not independently prognostic after CAPRA adjustment, did not outperform CAPRA, and was not designed for TMAs, requiring further refinement and validation.
limitation: Model was originally developed for whole slide biopsy specimens and tested on TMA spots, did not outperform established clinical tools, and authors note need for further refinement and validation in diverse settings.
tag: Model-prefilled trace
key_points: Study applied MMAI biopsy model to a tissue microarray of 424 prostatectomy cases with long-term follow-up, generating scores for 414 patients (98%). | At 10 years, recurrence-free and metastasis-free survival were 74% and 96%, respectively. | Correlation between MMAI and either CAPRA or CCP was modest (r < 0.35). | Combined MMAI and CCP model had c-index 0.76 for metastasis, comparable to CAPRA c-index 0.75.
rundown: Researchers applied the biopsy-validated MMAI model, using digitized pathology images and clinical variables, to a tissue microarray of prostatectomy cases with long-term follow-up.

In univariable analysis MMAI was associated with BCR and metastasis, remained significant when adjusted for genomic CCP score but not after adjustment for CAPRA, and the MMAI plus CCP combination achieved c-index 0.76 for metastasis.
sources:
- peer_reviewed | JNCI: Journal of the National Cancer Institute | https://doi.org/10.1093/jnci/djag210 | 2026-07-10
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

9ab5a0f023213d7e69a008455ea23d083a7fbeab94eef3db0fa696a3f5352d3c

previous

0000000000000000000000000000000000000000000000000000000000000000